|
|||
Aveo Pharmaceuticals (AVEO)0.85 unch (unch) 06/03/19 [NASDAQ]
0.84 x 1 0.85 x 12
POST-MARKET 0.83 -0.02 (-2.35%) 19:30 ET
for Mon, Jun 3rd, 2019
|
|||
Chart Link⇓ |
|||
https://www.barchart.com/stocks/quotes/Aveo |
|||
https://finance.yahoo.com/quote/AVEO |
|||
https://www.gurufocus.com/stock/aveo |
|||
|
|||
|
|||
DESCRIPTION:AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company’s lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company’s next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. |
|||
Notes AA | |||
Notes AR | |||
Aveo Pharmaceuticals (AVEO)
(AVEO)
0.85 unch (unch) 06/03/19 [NASDAQ]
0.84 x 1 0.85 x 12
POST-MARKET 0.83 -0.02 (-2.35%) 19:30 ET
QUOTE OVERVIEW for Mon, Jun 3rd, 2019
Category: Pharma & Health
Reviews
There are no reviews yet.
Related products
Pharma & Health
Pharma & Health
Current Stocks
Pharma & Health
Pharma & Health
Pharma & Health
Pharma & Health
Pharma & Health
Be the first to review “Aveo Pharmaceuticals (AVEO)”